Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Trimodality therapy with or without adjuvant Durvalumab to treat patients with bladder cancer Ended

2024-512502-26-00 Muscle-invasive bladder cancer 4 2019-11-06
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in pati… Ended

2023-509463-24-01 metastatic pancreatic cancer 4 2019-11-04
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended

2023-507443-10-00 Patients with somatostatin receptor positive, well-diff 5 2019-11-04
EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab ver… Ended

2023-508853-13-00 Oropharyngeal Squamous Cell Carcinoma 4 2019-10-31
This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab… Ended

2023-509276-42-00 Children and Adolescents with Cancers Harboring V600 mu 6 2019-10-30
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Different types of advanced cancer 3 2019-10-30
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended

2024-510776-20-00 Female or male patients with histologically confirmed H 5 2019-10-25
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended

2023-507678-42-00 Non Small Cell Lung Cancer; Medullary Thyroid Cancer; C 6 2019-10-24
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after i… Ended

2024-512581-34-00 EGFRm+ and MET+, Locally Advanced or Metastatic Non Sma 4 2019-10-23
Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9… Ended

2024-511849-19-00 Luminal B Breast Cancer 4 2019-10-17
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i… Ended

2024-515616-47-00 Metastatic Renal Cell Carcinoma 5 2019-10-03
Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended

2023-503425-18-00 Metastatic Solid Tumors 1 2019-10-02
GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended

2023-508526-10-00 Malignant solid tumors: Patients with relapsed or refra 7 2019-10-01
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas Ended

2023-507886-25-00 Previously untreated and symptomatic patients with hist 4 2019-09-27
A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu… Ended

2023-504624-25-00 Advanced Non-Small Cell Lung Cancer 4 2019-09-26
Imaging Perfusion Restrictions from Extracellular Solid Stress - An open-label losartan study Ended

2023-507575-22-00 Glioblastoma - newly diagnosed and recurrent tumors (St 4 2019-09-25
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended

2022-502658-15-00 Resectable Stage II-IIIB Non-small cell lung cancer 5 2019-09-22
A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended

2023-504821-38-00 Classical Hodgkin lymphoma in children and young adults 4 2019-09-19
EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER Ended

2024-514604-14-00 Muscle-invasive bladder cancer 4 2019-09-18
Trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failur… Ended

2024-512555-21-00 Metastatic colorectal cancer 5 2019-09-18
An efficacy and safety study of 2-OHOA in patients with glioblastoma Ended

2024-511542-39-00 Newly diagnosed primary glioblastoma multiforme (ndGBM) 10 2019-09-16
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11